UTI CRISIL SDL Maturity June 2027 Index Fund - Direct Plan - Growth Option

UTI CRISIL SDL Maturity June 2027 Index Fund - Direct Plan - Growth Option holds up reasonably well within the Index Funds category, backed by a 5-star rating. TopFund's composite Health Score, which weighs rating, 3-year CAGR, expense ratio and fund size, puts it at 76/100.

Cost: At 0.19%, the expense ratio is meaningfully cheaper — about 54% below the Index Funds category average of 0.41% (based on 857 comparable funds). Lower costs compound in your favour over long holding periods.

Risk-adjusted performance: Over the trailing 1-year period, the fund shows a negative Sharpe ratio of -0.13 — over the past year, returns haven't kept pace with the volatility involved, even before accounting for the risk-free rate. Separately, annualised volatility of 0.73% is on the lower side, suggesting a comparatively smoother ride.

Who should invest: This fund is best suited to cost-conscious investors happy to simply match the market rather than try to beat it. The High risk rating means near-term volatility should be expected — this isn't a fund to check daily.